The DEA opened formal proceedings Monday on a proposal to move marijuana from Schedule I to Schedule III of the Controlled Substances Act - the most consequential federal drug policy proceeding in decades. The hearing, held at DEA headquarters in Arlington, Virginia, draws testimony from physicians, researchers, public health advocates, and industry critics, and its outcome will shape federal cannabis policy, taxation, and business operations for years to come.
For dispensary operators and multi-state operators tracking this closely, the stakes extend well beyond symbolism. A Schedule III designation would redefine marijuana's federal legal standing - carrying direct implications for business tax treatment, research access, and regulatory structure. Operators in markets with active medical programs are watching with particular attention; for those managing both medical and adult-use operations under state licensure, federal classification affects everything from banking relationships to how insurers and institutional investors view the sector. State-regulated markets such as Maryland - where the medical-to-adult-use transition has introduced new compliance demands for licensed retailers - offer a window into how federal reclassification could ripple through existing regulatory frameworks; operators in those markets can learn more about how state-level requirements interact with federal policy pressure.
The single most tangible business implication on the table is Section 280E of the federal tax code. Currently, because marijuana remains Schedule I, cannabis businesses cannot deduct ordinary business expenses - payroll, rent, utilities, marketing - from their federal taxable income. That's a structural disadvantage that no other legal industry absorbs. Schedule III status would place marijuana outside 280E's reach, allowing licensed operators to take standard business deductions. For dispensaries running on thin margins - and many are - that shift could meaningfully alter unit economics without a single change to state law.
What the Opposition Is Actually Arguing
The proceeding is not a rubber stamp. Organizations opposing reclassification - including Smart Approaches to Marijuana, led by former White House drug policy adviser Dr. Kevin Sabet - plan to argue the proposal fails to meet the legal and scientific standards required under federal statute. Their core claims center on increased potency in today's commercial cannabis products, risks of psychosis and addiction, harm to developing adolescent brains, and what they characterize as insufficient clinical evidence to justify a Schedule III designation. SAM has also challenged the administration's process in court, arguing the rulemaking itself was procedurally deficient.
That legal challenge matters for operators. If the reclassification process is successfully contested on procedural grounds, the timeline - already measured in years - extends further. Businesses that have built financial projections around a 280E resolution could find themselves absorbing that tax burden indefinitely. The regulatory uncertainty isn't new to this industry, but this particular hearing creates a moment where the window either opens or stays shut for the foreseeable future.
The Medical Evidence Problem Isn't Going Away
Supporters of rescheduling, including physicians who recommend medical cannabis to patients, argue the change would better align federal classification with current clinical practice and open pathways for more rigorous large-scale research. Here's the catch: even advocates acknowledge the evidentiary base has real gaps. There is a documented shortage of large, high-quality randomized clinical trials on marijuana's therapeutic efficacy. Product quality is inconsistent across state markets. Prescribing guidelines for physicians remain thin. And concerns about impaired driving, adolescent brain development, dependence, and use during pregnancy are not resolved by reclassification alone.
What Schedule III would change is the federal research framework - making it substantially easier for institutions to study cannabis under controlled conditions. That matters for the longer arc of the industry's legitimacy. An estimated 3.7 million patients use medical marijuana in the United States, across programs operating in 40 states. The clinical infrastructure to serve them has grown faster than the evidence base supporting it. Rescheduling could begin to close that gap, but not immediately and not automatically.
What Operators Should Actually Be Tracking
For dispensary owners and compliance teams, the immediate practical question isn't whether rescheduling passes philosophical muster - it's what changes operationally and when. A few things to watch:
- 280E exposure: Until reclassification is finalized and legally settled, cannabis businesses remain subject to 280E. No change in accounting treatment should be made in anticipation of a ruling.
- Federal banking access: Rescheduling does not legalize cannabis federally or resolve the banking access problem on its own. The SAFER Banking Act remains a separate legislative track.
- State compliance obligations: Seed-to-sale tracking, COA requirements, compliant packaging, and excise tax obligations are all state-administered. They don't move with federal classification.
- Research and product standards: If rescheduling accelerates federal research, pressure for national manufacturing and testing standards will follow. Operators should expect that regulatory floor to rise over time.
The hearing will run through expert testimony from medical, scientific, and advocacy organizations. A final ruling, if it comes, would still require additional regulatory steps. This isn't the end of the process. But it is the clearest signal in years that federal cannabis policy is under active revision - and that operators, compliance officers, and investors need to treat that revision as a real planning variable, not background noise.
